PANTARHIN PHARMA INC. introduces BELACT®, a biotechnologically produced enzyme with a dual action approach, merging the functionalities of PH20 and HYAL4 into one molecule. This groundbreaking innovation represents the world’s first enzyme capable of efficiently breaking down both hyaluronic acid and sulfated glycosaminoglycans. These are key components of the extracellular matrix significantly involved in the development of atherosclerosis.
BELACT®’s unique mechanism targets the very building blocks of atherosclerotic plaques: proteoglycans and hyaluronic acid. Unlike current treatments that often stabilize or bypass deposits, BELACT® actively reduces them while preserving the structural integrity of blood vessels. This ensures that the vessel wall’s natural repair mechanisms can proceed without hindrance, promoting long term vascular health and stability.
The benefits of BELACT® extend beyond mere symptom management. By addressing the root cause of the pathophysiology, it facilitates the biological breakdown of plaque, and allows blood vessels to regain their natural elasticity. Its recombinant production ensures sustainability and compliance with GMP guidelines. Standardized in vitro tests show a significantly higher specific activity compared to established animal hyaluronidase preparations.
With a similarity to human enzymes, BELACT® boasts an expected good tolerability, confirmed by preclinical and clinical studies that demonstrate its safety profile and appropriate dosage. The process is industrially scalable, promising a reliable supply even for large patient populations. BELACT® effectively cleans up the vessels from the inside by breaking down pathological deposits without damaging healthy vascular tissue, offering a revolutionary approach to atherosclerosis treatment.